Trial reportBioMed research international2020
High Expression of Both Resistin and Fascin-1 Predicts a Poor Prognosis in Patients with Colorectal Cancer.
Trial report in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Fascin-1 expression in non-small cell lung cancer and its diagnostic implications.Discover oncology · 2026Article
- Upregulation of Caveolin-1 in breast cancer and its potential value in distinguishing TNBC from non-TNBC: an immunohistochemical study.Frontiers in oncology · 2026Article
- Caveolin-1 is upregulated in gastric cancer and is associated with tumor progression and prognosis in patients.International journal of clinical and experimental pathology · 2026Article
- Relationships between nutritional status and serum adipokine levels with chemotherapy efficacy in late-stage colorectal cancer patients.International journal of colorectal disease · 2025Article
- Expression of Insulin-like growth factor 2 mRNA-binding protein 3 and its diagnostic value in breast cancer.Frontiers in oncology · 2025Article
- Relevance and mechanism of STAT3/miR-221-3p/Fascin-1 axis in EGFR TKI resistance of triple-negative breast cancer.Molecular and cellular biochemistry · 2024Article
- An Updated Review of Resistin and Colorectal Cancer.Cureus · 2024Review
- Expression of Fascin-1 and its diagnostic value in liver cancer.Scientific reports · 2024Article
- Fascin-1 in Cancer Cell Metastasis: Old Target-New Insights.International journal of molecular sciences · 2023Review
- Inhibition of NLRP3 by Fermented Quercetin Decreases Resistin-Induced Chemoresistance to 5-Fluorouracil in Human Colorectal Cancer Cells.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Upregulated WTAP expression appears to both promote breast cancer growth and inhibit lymph node metastasis.Scientific reports · 2022Article
- Fascin-1: Updated biological functions and therapeutic implications in cancer biology.BBA advances · 2022Review
- Upregulated WTAP expression in colorectal cancer correlates with tumor site and differentiation.PloS one · 2022Article
- Review
- Fascin-1 and its role as a serological marker in prostate cancer: a prospective case-control study.Future science OA · 2021Article
- Emerging Role of Fascin-1 in the Pathogenesis, Diagnosis, and Treatment of the Gastrointestinal Cancers.Cancers · 2021Review
- The Adipokine Component in the Molecular Regulation of Cancer Cell Survival, Proliferation and Metastasis.Pathology oncology research : POR · 2021Review
- Subcellular localization of HMGB1 in colorectal cancer impacts on tumor grade and survival prognosis.Scientific reports · 2020Article
- Combined High Resistin and EGFR Expression Predicts a Poor Prognosis in Breast Cancer.BioMed research international · 2020Article
- Downregulated METTL14 Expression Correlates with Breast Cancer Tumor Grade and Molecular Classification.BioMed research international · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emerging evidence indicates that resistin and fascin-1 may possess a causal role in the development of several types of cancers. However, the clinical significance of resistin expression in colorectal cancer (CRC) tissues is unclear, and there are no reports of any correlation between resistin and fascin-1. Our analyses explored the expression of resistin in CRC tissue and analyzed the clinical and prognostic significance of the observed positive correlation between resistin and fascin-1. The rate of strongly positive resistin expression (27.5%) was significantly higher in CRC tissues than in normal colorectal tissues (5.2%). Strongly positive resistin expression is related to multiple poor prognostic factors in CRC, including depth of tumor invasion, lymph node metastasis, and tumor stage. In this study, survival was worse in CRC patients with high levels of both resistin and fascin-1 expression than in those with high levels of only one protein or normal levels of both proteins. We suggest that a combined high level of resistin and fascin-1 expression correlates reliably with survival in CRC, so it may serve as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.